sponsored
PatientsVille.com Logo

PatientsVille

Immunoglobulins Medical Research Studies

Up-to-date List of Immunoglobulins Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Immunoglobulins Medical Research Studies

Rank Status Study
1 Recruiting Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Condition: Cytomegalovirus Congenital Infection
Intervention: Biological: standard intravenous immunoglobulin
Outcome Measures: Prevention of neurological damage due to Cytomegalovirus congenital infection;   Evaluate safety of aspecific Immunoglobulins in pregnant women with primary CMV infection
2 Recruiting Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response
Condition: Rabies
Intervention: Biological: Human Rabies Immune Globulin
Outcome Measures: Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg;   Number of participants who have Rabies Neutralizing antibody titers above protective levels.
3 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
Outcome Measures: Incidence of dose-limiting toxicities to determine MTD of radiation delivered to normal organ by iodine I 131 monoclonal antibody BC8;   Rates of transplant-related mortality for patients receiving iodine I 131 monoclonal antibody BC8 when combined with 2 Gy TBI + CSP/MMF;   Disease response in patients receiving iodine I 131 monoclonal antibody BC8 combined with fludarabine phosphate, 2 Gy TBI, CSP, MMR and HLA-matched related or unrelated allogeneic HSCT;   Disease-free survival in patients receiving iodine I 131 monoclonal antibody BC8 combined with fludarabine phosphate, 2 Gy TBI, CSP, MMR and HLA-matched related or unrelated allogeneic HSCT;   Rates of donor chimerism and graft-versus-host disease
4 Recruiting Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: indium In 111 anti-CD45 monoclonal antibody BC8;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Procedure: peripheral blood stem cell transplantation
Outcome Measures: MTD of yttrium-90 anti-CD45 monoclonal antibody BC8 before stem cell transplant defined as dose-limiting toxicity rate of 25% graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0;   Overall response rate;   Overall survival;   Progression-free survival;   Tumor to normal organ ratios
5 Not yet recruiting Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
Condition: Rabies
Intervention: Biological: rabies vaccine
Outcome Measures: Rabies Neutralizing antibody titers in volunteers who receive rabies vaccination on day 0,3,7,14;   Rabies Neutralizing antibody titers in volunteers who receive rabies vaccination on day 0,3,7,28
6 Recruiting Immunoglobulin Dosage and Administration Form in CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy;   Hemolytic Anemia
Intervention: Drug: Immunoglobulins
Outcome Measures: Variation in blood hemoglobin during treatment with IVIG and SCIG;   Variation in muscle strength during treatment with two preparations of SCIG;   Variation in muscle strength during treatment with IVIG and SCIG;   Variation in blood hemoglobin during treatment with two preparations of SCIG
7 Recruiting Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
Condition: Rheumatoid Arthritis
Intervention: Other: no intervention
Outcome Measures: Percentage of Patients Positive for Antidrug Antibodies Among Those Treated with etanercept Versus Those Treated with Monoclonal Antibodies (adalimumab or infliximab);   Proportion of patients with Low Disease Activity (LDA);   Concentration of Serotype-Specific Antibodies;   Proportion of Patients Positive for Antidrug Antibodies;   Clinical Disease Activity Index (CDAI) Scores;   Simplified Disease Activity Index (SDAI) Scores;   Disease Activity Score, 28 Joint Count, calculated with erythrocyte sedimentation rate (DAS28-ESR);   Disease Activity Score, 28 Joint Count, calculated with c-reactive protein (DAS28-CRP);   Health Assessment Questionnaire (Disability and Discomfort Scales ) (HAQ-DI) Scores;   Spearman's Correlation Coefficient of Antidrug Antibody Titers with DAS28-ESR;   Spearman's Correlation Coefficient of Antidrug Antibody Titers with DAS28-CRP;   Spearman's Correlation Coefficient of Antidrug Antibody Titers with CDAI;   Spearman's Correlation Coefficient of Antidrug Antibody Titers SDAI;   Spearman's Correlation Coefficient of Antidrug Antibody Titers with Trough Drug Concentration
8 Not yet recruiting Identification of Donor Specific B Cells and Antibody Mediated Rejection
Condition: Sensitized Kidney Transplant Recipients
Intervention:
Outcome Measures: Donor specific B (DSB) cell populations are reduced after desensitization.;   Correlation of DSB to incidence of antibody mediated rejection;   B-cell activating factor (BAFF) levels increase after desensitization;   A proliferation inducing ligand (APRIL) levels increase after desensitization
9 Unknown  Intravenous Immunoglobulins in Complex-regional Pain Syndrome
Condition: Complex Regional Pain Syndrome Type 1
Intervention: Biological: intravenous Immunoglobulins
Outcome Measures: Change in impairment Level SumScore (ISS);   Pain disability score;   Quality of life (SF-36);   Titer of surface-binding neuronal autoantibodies in the serum;   Serum concentration of B-cell activating factors BAFF, APRIL
10 Recruiting A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Humanized anti-GD2 antibody;   Drug: Chemotherapy;   Other: Cytokines;   Biological: Natural killer cells
Outcome Measures: Number of patients experiencing unacceptable toxicity associated with humanized anti-GD2 antibody/chemotherapy (course 1) and anti-GD2 antibody/chemotherapy/NK cells (course 2).;   Response to treatment;   Time to progression.;   Event free survival.;   Overall survival
11 Unknown  Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea
Conditions: Sydenham Chorea;   Post Streptococcal Movement Disorder
Interventions: Biological: Intravenous immunoglobulin;   Drug: standard interventions penicillin VK and haloperidol
Outcome Measures: improved scores on the sydenham chorea assessment charts;   improved quality of life
12 Recruiting Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: MTD of yttrium Y 90 anti-CD45 monoclonal antibody BC8, defined as the dose that is associated with a true dose-limiting toxicity (DLT) rate of 25%;   Progression-free survival (PFS) following ASCT;   The lowest antibody (yttrium Y 90 anti-CD45 monoclonal antibody BC8) dose (mg/kg) that is consistent with a favorable biodistribution rate >= 80% in lymphoma patients;   Estimated dose to tumor sites based on the tumor to normal organ ratios derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of yttrium Y 90 anti-CD45 monoclonal antibody BC8
13 Recruiting Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
Conditions: HIV Infection;   Monoclonal Antibody, Human;   HIV Antibodies;   VRC01 Monoclonal Antibody;   Neutralizing Antibody
Intervention: Drug: VRC-HIVMAB060-00-AB
Outcome Measure: This is a Phase 1 study with primary outcomes of safety and pharmacokinetics
14 Recruiting Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: NPB-01
Outcome Measures: Change from Baseline Quantification of nerve and spinal cord impairment (QOSI) at 29 days;   Change from Baseline Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) at 29 days;   Change from Baseline anti-aquaporin 4 antibody at 29 days
15 Recruiting Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Conditions: Antibody-mediated Rejection;   Humoral Rejection
Interventions: Drug: Eculizumab;   Biological: Immunoglobulin;   Procedure: Plasmapheresis
Outcome Measure: Change in eGFR
16 Not yet recruiting A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients
Condition: Renal Transplant Recipients With Anti-HLA Antibody (DSA) Positivity
Intervention:
Outcome Measures: This trial with evaluate the treatment effect of maintenance intravenous immunoglobulin therapy on graft survival and glomerular filtration rates in renal transplant recipients who present with anti-human leukocyte antigen (HLA) antibodies (DSA).;   This trial will provide an estimate of the kinetics of the change in anti-HLA antibodies Class I and/or Class II, as it relates to IVIg therapy response rates.
17 Recruiting Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
Condition: Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Interventions: Drug: TA-650;   Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
Outcome Measures: Defervescence rate within 48 hours after the start of the study drug administration;   Duration of fever;   Incidence of coronary artery lesions
18 Unknown  Immunoadsorption and Immunoglobulin Substitution for Heart Failure After Myocardial Infarction
Conditions: Heart Failure;   Coronary Heart Disease
Intervention: Device: Immunoadsorption / Immunoglobulin substitution
Outcome Measures: left-ventricular ejection fraction as measured by echocardiography;   cardiac index;   systemic vascular resistance;   pulmonary vascular resistance;   n-terminal pro-BNP concentration (serum);   peak oxygen uptake (spiroergometric);   dyspnoea symptoms / NYHA classification
19 Recruiting Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD
Condition: Advanced COPD (GOLD Stage 3 or 4) With Cachexia
Interventions: Dietary Supplement: Serum bovine immunoglobulin (SBI) medical food;   Dietary Supplement: Placebo (for serum bovine immunoglobulin)
Outcome Measures: The subtracted differences in BMI, body fat measurement, and grip strength between participants receiving SBI or placebo at baseline and 6 months.;   The subtracted differences between FEV1 and COPD Assessment Test scores in patients receiving SBI or placebo at baseline and 6 months.
20 Recruiting Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: Estimation of the maximum tolerated dose of I-131-BC8 that can be delivered prior to transplant;   Overall survival;   Progression-free survival;   Relapse rate;   Incidence of adverse events/toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events

These studies may lead to new treatments and are adding insight into Immunoglobulins etiology and treatment.

A major focus of Immunoglobulins research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Immunoglobulins